Amgen vs Eli Lilly and: Business Model & Financial Comparison 2026
Amgen · Healthcare / Drug Manufacturers - General·Eli Lilly and · Healthcare / Drug Manufacturers - General
Financial Comparison
| Metric | AMGNAmgen | LLYEli Lilly and |
|---|---|---|
| Market Cap | $198.26B | $874.66B |
| Revenue (TTM) | $36.75B | $65.18B |
| Revenue Growth | 8.6% | 42.6% |
| Gross Margin | 70.8% | 83.0% |
| Operating Margin | 30.5% | 44.9% |
| Net Margin | 21.0% | 31.7% |
| Return on Equity | 106.1% | 101.2% |
| P/E (Trailing) | 25.8x | 42.5x |
| P/E (Forward) | 15.8x | 23.3x |
| Free Cash Flow | $7.50B | $1.95B |
| Cash | $9.13B | $7.27B |
| Total Debt | $55.44B | $43.87B |
Data sourced from Yahoo Finance. Green highlights indicate better performance for that metric. Use the interactive tool for real-time data.
Business Model Comparison
Amgen
Amgen Inc. stands as a leading company in Healthcare. Generating $36.75 billion in annual revenue (growing 8.6% year-over-year) and carrying a market capitalization of $198.16 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, Amgen Inc. continues to execute on a multi-year strategic vision that balances growth investment with s…
Full Amgen analysis →Eli Lilly and
Eli Lilly and Company stands as a leading company in Healthcare. Generating $65.18 billion in annual revenue (growing 42.6% year-over-year) and carrying a market capitalization of $880.04 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, Eli Lilly and Company continues to execute on a multi-year strategic vision that balances g…
Full Eli Lilly and analysis →SWOT Analysis Comparison
Strengths
Amgen
- With a market capitalization of $198.16B, Amgen Inc. is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital access that smal
- Amgen Inc.'s gross margin of 70.8% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 30.5% demonstrates discipline
- A return on equity of 106.1% demonstrates that Amgen Inc. generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages.
Eli Lilly and
- With a market capitalization of $880.04B, Eli Lilly and Company is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital acces
- Eli Lilly and Company's gross margin of 83.0% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 44.9% demonstrates
- Revenue grew 42.6% year-over-year to $65.18B, indicating strong demand for Eli Lilly and Company's products and services and outperformance relative to many industry peers.
Weaknesses
Amgen
- With a debt-to-equity ratio of 640.3, Amgen Inc. carries significant debt relative to equity. While manageable given its cash flow, elevated leverage limits financial flexibility and increases vulnera
Eli Lilly and
- With a debt-to-equity ratio of 165.3, Eli Lilly and Company carries significant debt relative to equity. While manageable given its cash flow, elevated leverage limits financial flexibility and increa
Opportunities
Amgen
- Amgen Inc. operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this envi
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Amgen I
- Earnings growth of 112.1% YoY demonstrates Amgen Inc.'s ability to convert revenue growth into shareholder value. Analysts project continued earnings expansion driven by operating leverage as fixed co
Eli Lilly and
- Eli Lilly and Company operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains i
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Eli Lil
- Earnings growth of 51.4% YoY demonstrates Eli Lilly and Company's ability to convert revenue growth into shareholder value. Analysts project continued earnings expansion driven by operating leverage a
Threats
Amgen
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Amgen Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scena
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Amgen Inc.'s busine
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Eli Lilly and
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Eli Lilly and Company's revenue is not fully insulated from macroeconomic cycles, and a rece
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Eli Lilly and Compa
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Compare any 2–4 companies with live data
The interactive comparison tool lets you select any companies, see real-time metrics, and export a side-by-side report.
Open Comparison ToolAmgen vs Eli Lilly and: FAQ
- Is Amgen bigger than Eli Lilly and?
- By market capitalization, Eli Lilly and is larger at $874.66B vs Amgen's $198.26B.
- Which has better profit margins — Amgen or Eli Lilly and?
- Eli Lilly and has higher net profit margins (31.7%) compared to Amgen (21.0%). Gross and operating margins are compared in the table above.
- What sectors do Amgen and Eli Lilly and operate in?
- Amgen operates in the Healthcare sector (Drug Manufacturers - General). Eli Lilly and operates in the Healthcare sector (Drug Manufacturers - General).
- How does Amgen's revenue compare to Eli Lilly and's?
- Amgen generates $36.75B in annual revenue (TTM) while Eli Lilly and generates $65.18B. Eli Lilly and is the larger company by revenue as of 2026.